Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P01138
UPID:
NGF_HUMAN
Alternative names:
-
Alternative UPACC:
P01138; A1A4E5; Q6FHA0; Q96P60; Q9P2Q8; Q9UKL8
Background:
Beta-nerve growth factor (NGF) plays a pivotal role in the development and maintenance of the sympathetic and sensory nervous systems. It acts as an extracellular ligand for NTRK1 and NGFR receptors, initiating signaling cascades that regulate neuronal proliferation, differentiation, and survival. The precursor form of NGF, proNGF, has contrasting roles, promoting neuronal apoptosis and affecting neuronal growth cone dynamics.
Therapeutic significance:
NGF's involvement in hereditary sensory and autonomic neuropathy type 5 (HSAN5), characterized by loss of pain perception and impaired temperature sensitivity, underscores its therapeutic potential. Understanding NGF's dual roles offers insights into developing treatments for sensory and autonomic nervous system disorders.